Literature DB >> 12519890

Amplification and overexpression of mutant RET in multiple endocrine neoplasia type 2-associated medullary thyroid carcinoma.

Steve C Huang1, Joshua Torres-Cruz, Svetlana D Pack, Christian A Koch, Alexander O Vortmeyer, Poonam Mannan, Irina A Lubensky, Robert F Gagel, Zhengping Zhuang.   

Abstract

We have previously identified two second hit mechanisms involved in the development of multiple endocrine neoplasia type 2 (MEN 2)-associated tumors: trisomy 10 with duplication of the mutant RET allele and loss of the wild-type RET allele. However, some of the MEN 2-associated tumors investigated did not demonstrate either mechanism. Here, we studied the TT cell line derived from MEN 2-associated medullary thyroid carcinoma with a RET germline mutation in codon 634, for alternative mechanisms of tumorigenesis. Although we observed a 2:1 ratio between mutant and wild-type RET at the genomic DNA level in this cell line, fluorescence in situ hybridization analysis revealed neither trisomy 10 nor loss of the normal chromosome 10. Instead, a tandem duplication event was responsible for amplification of mutant RET. In further studies we could for the first time demonstrate that the genomic chromosome 10 abnormalities in this cell line cause an increased production of mutant RET mRNA. These findings provide evidence for a third second hit mechanism resulting in overrepresentation and overexpression of mutant RET in MEN 2-associated tumors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12519890     DOI: 10.1210/jc.2002-021254

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

Review 1.  Evolution of Our Understanding of the Hyperparathyroid Syndromes: A Historical Perspective.

Authors:  Stephen J Marx; David Goltzman
Journal:  J Bone Miner Res       Date:  2018-12-10       Impact factor: 6.741

Review 2.  Molecular pathogenesis of MEN2-associated tumors.

Authors:  Christian A Koch
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

3.  Novel germline mutation in the transmembrane region of RET gene close to Cys634Ser mutation associated with MEN 2A syndrome.

Authors:  M Poturnajova; V Altanerova; L Kostalova; J Breza; C Altaner
Journal:  J Mol Med (Berl)       Date:  2004-12-09       Impact factor: 4.599

Review 4.  Pheochromocytoma: implications in tumorigenesis and the actual management.

Authors:  U Shah; A Giubellino; K Pacak
Journal:  Minerva Endocrinol       Date:  2012-06       Impact factor: 2.184

Review 5.  From transcriptional profiling to tumor biology in pheochromocytoma and paraganglioma.

Authors:  Alberto Cascón; Daniel A Tennant
Journal:  Endocr Pathol       Date:  2012-03       Impact factor: 3.943

6.  Orolabial signs are important clues for diagnosis of the rare endocrine syndrome MEN 2B. Presentation of two unrelated cases.

Authors:  Agnes Sallai; Eva Hosszú; Péter Gergics; Károly Rácz; György Fekete
Journal:  Eur J Pediatr       Date:  2007-06-19       Impact factor: 3.183

7.  Somatic VHL gene alterations in MEN2-associated medullary thyroid carcinoma.

Authors:  Christian A Koch; Frederieke M Brouwers; Alexander O Vortmeyer; Andrea Tannapfel; Steven K Libutti; Zhengping Zhuang; Karel Pacak; Hartmut P H Neumann; Ralf Paschke
Journal:  BMC Cancer       Date:  2006-05-17       Impact factor: 4.430

8.  Case reports: old-timers and evergreens.

Authors:  C A Koch; T Fülöp
Journal:  J Med Case Rep       Date:  2018-11-27

9.  Retroposed copies of RET gene: a somatically acquired event in medullary thyroid carcinoma.

Authors:  Larissa V Bim; Fábio C P Navarro; Flávia O F Valente; José V Lima-Junior; Rosana Delcelo; Magnus R Dias-da-Silva; Rui M B Maciel; Pedro A F Galante; Janete M Cerutti
Journal:  BMC Med Genomics       Date:  2019-07-09       Impact factor: 3.063

10.  Genetic Predisposition to Numerous Large Ulcerating Basal Cell Carcinomas and Response to Immune Therapy.

Authors:  Bahar Dasgeb; Youssefian Leila; Amir Hossein Saeidian; Jun Kang; Wenyin Shi; Elizabeth Shoenberg; Adam Ertel; Paolo Fortina; Hassan Vahidnezhad; Jouni Uitto
Journal:  Int J Dermatol Venereol       Date:  2021-06-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.